Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Michele Brignole,
Empirical or tilt-guided therapy of neurally-mediated syncope have often failed to show a benefit. Recently, a new strategy for the assessment and treatment of neurally mediated syncope has been proven to be safe and effective at reducing the recurrence of syncope. This is based on simple initial symptom evaluation, early application of a diagnostic implantable loop recorder, and delayed specific therapy upon documentation of the cause of syncope.
In conventional practice - besides electrocardiographic (ECG) documentation of syncope - therapy of neurally-mediated syncope (NMS) has been principally empirical or guided by the results of tilt-table testing.
Controlled trials of tilt-guided therapy, however, have often failed to show a benefit and the evidence of efficacy for empirical therapy of neurally-mediated syncope is weak (1,2,3). Specifically, the efficacy of pacemaker therapy was questioned after two recent controlled trials failed to prove the superiority of cardiac pacing over placebo in unselected patients with positive tilt testing (4,5). This is not surprising if we consider that the mechanism of syncope is heterogeneous and therefore there is the need to assign a specific therapy for each individual patient.
The International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) (6) was a multi-center, prospective, observational study enrolling 442 patients with a diagnosis of suspected NMS from centers across Europe and the USA. The study assessed the effectiveness of a diagnostic and treatment strategy based on the initial evaluation described above, early implantable loop recorder (ILR) implantation, and ILR-based specific therapy after syncope recurrence.
It is generally agreed that, in accordance with the guidelines of the European Society of Cardiology (1,2), by relatively straightforward initial evaluation (patient history, physical examination, standard electrocardiogram, and measurement of supine/upright blood pressure), it is possible to risk-stratify patients with syncope. Specifically, this approach can effectively identify patients likely to have cardiac syncope, and who would benefit from further cardiovascular investigations. Furthermore, based on the initial evaluation, a neurally-mediated mechanism can be suspected, irrespective of the results of tilt testing (7,8,9). Therefore, based only on this initial evaluation, a group of patients with suspected NMS can be identified with a high level of certainty, and followed through the implantation of a loop recorder (ILR). The cost of the ILR (Reveal, Medtronic) is approximately € 1500.
In general, initial treatment of all forms of neurally-mediated reflex syncope comprises education regarding avoidance of triggering events, recognition of premonitory symptoms, and maneuvers to abort a syncope episode. Additional treatment may be necessary in high-risk or high-frequency settings, such as when (1,2):
In these settings, long-term monitoring with an ILR may be appropriate.
In particular, in the ISSUE 2 study (6), only a minority of the patients ultimately received an ILR implantation. The ISSUE population was elderly, had a history of recurrent syncope beginning in middle or older ages and frequent injuries probably due to presentation without warning. Indeed, the mean age was >65 years, with a history of recurrent syncopes beginning in middle age or older; the number of syncopal episodes preceding study entry was between four and 10; median history of syncope was 7 years; 50% reported no warning at syncope onset; and 21% reported major injuries from at least one of the episodes (e.g., fractures, brain concussions); most patients (>85%) had normal ECGs and no structural heart disease. These findings partially differentiated these patient population from the general population of patients affected by neurally-mediated syncope.
Experience from ILR consistenly showed that the mechanism of syncope is heterogeneous with bradycardia or asystole accounting for approximately one-half of the syncope events (7,10,11,12). In ISSUE 2 in particular, among 106 ILR documented episodes:
Based on this approach the logical recommended mechanism-specific therapies are:
In the ISSUE 2-study, 53 patients received ILR-based specific therapy, mostly pacemaker therapy (n=47) and 50 patients received counseling (education and reassurance) and nonspecific therapy. Patient characteristics were well-matched for the two groups.
The 1-year recurrence rate in patients assigned to a specific therapy was 10% (burden 0.07?0.2 episodes per patient/year) compared with 41% (burden 0.83?1.57 episodes per patient/year) in the patients without specific therapy (80% relative risk reduction for patients, p=0.002, and 92% for burden, p=0.002). The 1-year recurrence rate in patients with pacemakers was 5% (burden 0.05±0.15 episodes per patient/year). Severe trauma secondary to syncope relapse occurred in 2%, mild trauma in 4% of the patients during the overall study period.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
A strategy based on early application of the ILR with therapy delayed until documentation of syncope allows a safe, specific and effective therapy for patients with recurrent suspected NMS. Further, based on the findings reported here, it seems reasonable to recommend that early ILR use become standard practice for management (diagnosis and treatment) of patients with severe recurrent suspected NMS.
1- Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Thomsen PE, van Dijk G, Fitzpatrick A, Hohnloser S, Janousek J, Kapoor W, Kenny RA, Kulakowski P, Masotti G, Moya A, Raviele A, Sutton R, Theodorakis G, Ungar A, Wieling W. Guidelines on management (diagnosis and treatment) of syncope – Update 2004 - Executive summary and recommendations. Eur Heart J 2004; 25, 2054–2072 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15541843&query_hl=1&itool=pubmed_docsum 2. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Thomsen PE, van Dijk G, Fitzpatrick A, Hohnloser S, Janousek J, Kapoor W, Kenny RA, Kulakowski P, Masotti G, Moya A, Raviele A, Sutton R, Theodorakis G, Ungar A, Wieling W Guidelines on management (diagnosis and treatment) of syncope – Update 2004. Europace 2004; 6, 467-537 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15519256&query_hl=1&itool=pubmed_docsum 3- Kapoor W. Is there an effective treatment for neurally-mediated syncope? JAMA 2003; 289: 2272-5 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12734140&query_hl=4&itool=pubmed_docsum 4- Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, Morillo C, Gent M for the VPS II investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II). JAMA 2003; 289: 2224-2229 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12734133&query_hl=6&itool=pubmed_docsum 5- Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M The vasovagal syncope and pacing trial (Synpace). A randomized placebo-controlled study of permanent pacing for treatment of recurrent vasovagal syncope. Eur Heart J 2004: 25: 1741–1748 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15451153&query_hl=9&itool=pubmed_docsum 6- Brignole M, Sutton R, Menozzi C, et al. Early application of an Implantable Loop Recorder allows a mechanism-based effective therapy in patients with recurrent suspected neurally-mediated syncope. Eur Heart J 2006 (in press) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15451153&query_hl=9&itool=pubmed_docsum 7. Moya A, Brignole M, Menozzi C, Garcia-Civera R, Tognarini S, Mont L, Botto G, Giada F, Cornacchia D Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001;104:1261-1267 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11673344&query_hl=11&itool=pubmed_docsum 8- Sheldon R, Rose S, Koshman M. Comparison of patients with syncope of unknown cause having negative or positive tilt-table tests. Am J Cardiol 1997; 80: 581-585 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9294985&query_hl=13&itool=pubmed_docsum 9- Grimm W, Degenhardt M, Hoffman J, Menz V, Wirths A, Maisch B. Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope. Eur Heart J 1997; 18: 1465-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9458453&query_hl=15&itool=pubmed_docsum 10- Krahn AD, Klein GJ, Yee R, Takle-Newhouse T, Norris C. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation 1999; 26: 99: 406-410 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9164718&query_hl=17&itool=pubmed_docsum 11- Krahn A, Klein G, Yee R, Skanes AC. Randomized assessment of syncope trial. Conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001;104:46-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11435336&query_hl=20&itool=pubmed_docsum 12- Farwell D, Freemantle N, Sulke N. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J 2004; 25: 1257-63 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15246645&query_hl=23&itool=pubmed_docsum
Dr M. Brignole Lavagna, Italy Member of the Committee for Scientific Initiatives of EHRA
© 2017 European Society of Cardiology. All rights reserved